Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Special Use Investigation of HALAVEN (HAL03T) - Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas

Trial Profile

Special Use Investigation of HALAVEN (HAL03T) - Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs Eribulin (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions
  • Acronyms HAL03T
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 11 Dec 2018 Planned End Date changed from 1 Nov 2018 to 1 Jan 2019.
    • 11 Dec 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Jan 2019.
    • 06 Sep 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top